|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3 Pt 2
|
|
pubmed:dateCreated |
1981-10-25
|
|
pubmed:abstractText |
The animal and human pharmacology of several new drugs (prazosin, trimazosin, pirbuterol, and carbazeran) useful in the treatment of congestive heart failure (CHF) is delineated in relation to the pharmacology of other agents employed for CHF management. Prazosin and trimazosin are selective alpha 1-blockers that cause a balanced increase in cardiac output (CO) and reduction in left ventricular filling pressure (LVFP); the reduction in diastolic blood pressure with these drugs is significantly related to increase in treadmill exercise, fall in LVFP, and increase in CO. Pirbuterol is a relatively selective beta 2-agonist with somewhat greater effects on CO than on LVFP. Early promise in CHF therapy is being shown by a novel series of cyclic adenosine monophosphate (cAMP) phosphodiesterase inhibitors with combined direct inotropic and vasodilator effects. Double-blind long-term studies demonstrate persistent efficacy of prazosin and trimazosin in CHF as measured by improvement in New York Heart Association functional class, treadmill exercise performance, and noninvasive measures of cardiac function; these data are supported by studies in which repeat cardiac catheterization has been performed after several months of therapy. Double-blind studies of other CHF drugs are in progress.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0002-8703
|
|
pubmed:author |
pubmed-author:BairdJ RJR,
pubmed-author:BlackburnK JKJ,
pubmed-author:CambridgeDD,
pubmed-author:ConstantineJ WJW,
pubmed-author:GhalyM SMS,
pubmed-author:HaydenM LML,
pubmed-author:McIlhennyH MHM,
pubmed-author:MooreP FPF,
pubmed-author:OlukotunA YAY,
pubmed-author:PullmanL GLG,
pubmed-author:SalsburgD SDS,
pubmed-author:SaxtonC ACA,
pubmed-author:ShevdeSS,
pubmed-author:TaylorC RCR
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
102
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
515-32
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:7023221-Animals,
pubmed-meshheading:7023221-Asthma,
pubmed-meshheading:7023221-Carbamates,
pubmed-meshheading:7023221-Cardiotonic Agents,
pubmed-meshheading:7023221-Cardiovascular Agents,
pubmed-meshheading:7023221-Clinical Trials as Topic,
pubmed-meshheading:7023221-Drug Evaluation,
pubmed-meshheading:7023221-Drug Evaluation, Preclinical,
pubmed-meshheading:7023221-Ethanolamines,
pubmed-meshheading:7023221-Heart Failure,
pubmed-meshheading:7023221-Hemodynamics,
pubmed-meshheading:7023221-Humans,
pubmed-meshheading:7023221-Hypertension,
pubmed-meshheading:7023221-Piperazines,
pubmed-meshheading:7023221-Prazosin,
pubmed-meshheading:7023221-Quinazolines,
pubmed-meshheading:7023221-Vasodilator Agents
|
|
pubmed:year |
1981
|
|
pubmed:articleTitle |
Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Review
|
